Synlogic

Synlogic is a biotechnology startup with a focus on developing innovative, orally administered biotherapeutics to revolutionize the treatment of severe diseases lacking effective therapeutic options. The company's late-stage pipeline is primarily directed towards addressing rare metabolic diseases, with its lead candidate, labafenogene marselecob (SYNB1934), currently undergoing evaluation as a potential therapy for phenylketonuria (PKU) in the Synpheny-3, a pivotal Phase 3 study. Furthermore, Synlogic has additional product candidates targeting conditions such as homocystinuria (HCU), enteric hyperoxaluria, gout, and cystinuria. The core of its pipeline is powered by the Synthetic Biotic platform, leveraging precise genetic engineering techniques applied to well-characterized probiotics, enabling the creation of GI-restricted, oral medications designed to consume or modify disease-specific metabolites. Notably, the company has a collaboration with Roche focused on inflammatory bowel disease (IBD) and a partnership with Ginkgo Bioworks in synthetic biology, contributing to two pipeline programs. Although the company was established in 2014, it recently secured a considerable $21.00M Post-IPO Equity investment on 29 September 2023. Synlogic's unique approach and diverse pipeline indicate its potential to create impactful solutions for unmet medical needs. For more details, visit www.synlogictx.com.